The results of CEL-SCI’s Phase 3 clinical trial study of investigational cancer immunotherapy, Multikine were recently published on ClinicalTrials.gov, and Kersten was there to give her explanation of the findings.
A key point that Kersten makes is that out of the radiation-only group in the study, 16% of patients had a tumor reduction of 30% or more before surgery. Also, five participants showed complete tumor regression.
Kersten will discuss how oncologists have reacted to data presented at major conferences in 2022, including ESMO and ASCO.
He then talks about the greatest market opportunity and problem in immunotherapy that CEL-SCI is trying to solve. He finishes by giving an outlook for what investors can expect from the company in the next 6 to 12 months.
About The Guest: Geert Kersten (CEO – CEL-SCI Corporation)
Geert Kersten, CEO of cancer company CEL-SCI Corporation since 1995, has been with the organization from its early days in 1987. A pioneer in cancer immunotherapy–a field that uses the body’s immune system to fight cancer cells–Kersten has navigated many challenging times within the volatile biotech industry successfully during his almost two decades of experience.
Not only does Geert Kersten believe in making the world a better place, but he also has experience and knowledge in finance and law. Mr. Kersten’s vision for CEL-SCI’s product, Multikine®, is that it will change how cancer is currently being treated for the better.
Prior to joining CEL-SCI, Mr. Kersten held positions at the law firm of Finley & Kumble and Source Capital, an investment banking company located in McLean, VA.
Mr. Kersten was born in Germany and received his undergraduate degree in accounting from Millfield School in England before studying at George Washington University, where he obtained an MBA. He later added a law degree (J.D.) from American University to his credentials. Additionally, Mr Kersten is the inventor of a patent for the use of Multikine in cholesterol management.
About CEL-SCI Corporation
CEL-SCI Corporation recently completed their head and neck Phase 3 clinical trial, IT-MATTERS. With a total of 928 patients, this study is now the largest one of its kind. The primary focus was to determine if Multikine would result in any benefits for survival rates or other clinic outcomes for those with locally advanced primary squamous cell carcinoma of the mouth and throat region (SCCHN), oral cavity, or soft palate . In order to adhere to international standards and practices ,the trial was conducted across 23 countries following all required protocols including Good Clinical Practices and International Council for Harmonization standards.
CEL-SCI initiated Phase 3 in early 2011 and enrolled 928 patients by September 2016. In order for the study to achieve its objective of displaying an overall survival benefit, CEL-SCI had to wait until 298 people died among the two groups being compared (which were equal in size). After meeting this criterion, The FDA awarded Multikine (Leukocyte Interleukin, Injection) Orphan Drug designation for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
Multikine is designed to enhance the immune system’s ability to target and attack tumors. Natural cytokines that help regulate the immune system make up this treatment, which doctors give to patients with previously untreated SCCHN before they start SOC (standard of care) regimen. The earlier this neoadjuvant cancer immunotherapy is administered, the more effective it appears to be.
To inquire about being a guest on this show or others please get in touch here: Contact Us
Please Like and Subscribe on YouTube to stay updated with future videos like these from other executives and CEO’s and subscribe to our newsletter for up to date notifications and information.
Neither Global Market Bulletin TV or any of its principals currently own or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, https://globalmarketbulletin.com/term…
Global Market Bulletin is a leading provider of stock market updates, economic news, and personalized investing guides.
Our team brings you the latest global financial information to help you make smart investment decisions.
Tracy Curley, Chief Financial Officer and interim-CEO of iSpecimen (NASDAQ: ISPC), joins host Leyla Gulen to discuss the launch of their new self-service Open Feasibilities Dashboard on Marketplace....